Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Overall Study	STARTED	Pembrolizumab	496
Overall Study	STARTED	Placebo	498
Overall Study	Treated	Pembrolizumab	488
Overall Study	Treated	Placebo	496
Overall Study	Continuing Study Treatment	Pembrolizumab	0
Overall Study	Continuing Study Treatment	Placebo	1
Overall Study	Completed Study Treatment	Pembrolizumab	298
Overall Study	Completed Study Treatment	Placebo	365
Overall Study	Discontinued Study Treatment	Pembrolizumab	190
Overall Study	Discontinued Study Treatment	Placebo	130
Overall Study	COMPLETED	Pembrolizumab	0
Overall Study	COMPLETED	Placebo	0
Overall Study	NOT COMPLETED	Pembrolizumab	496
Overall Study	NOT COMPLETED	Placebo	498

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03142334/flow